Schubert & Co’s Integra LifeSciences IART Stock Holding History

Schubert & Co’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-45	Closed	-$2.58K	–	722
2023 Q1	$2.58K	Buy	45 +5	+13%	+$282	﹤0.01%	783
2022 Q4	$2.24K	Buy	40 +4	+11%	+$204	﹤0.01%	813
2022 Q3	$2K	Buy	36 +8	+29%	+$410	﹤0.01%	820
2022 Q2	$2K	Buy	28 +13	+87%	+$781	﹤0.01%	791
2022 Q1	$1K	Buy	15 +4	+36%	+$263	﹤0.01%	737
2021 Q4	$1K	Buy	+11	New	+$744	﹤0.01%	693

Other funds holding IART

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schubert & Co's IART Position: Q2 2023 in Review

Schubert & Co sold out of Integra LifeSciences (IART) in Q2 2023, closing a stake of 45 shares — an estimated $2.58K sold.

Schubert & Co first reported a position in IART in Q4 2021 and held it in 6 quarters. The position peaked at $2.58K in Q1 2023. 283 funds tracked by Wall St. Rank hold IART as of Q2 2023.

Schubert & Co reported no remaining Integra LifeSciences position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 45 Integra LifeSciences shares in Q2 2023, an estimated $2.58K.
Schubert & Co first reported a position in Integra LifeSciences in Q4 2021 and held it in 6 quarters.
Schubert & Co's Integra LifeSciences position peaked at $2.58K in Q1 2023.
283 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.